keynote-921: pembrolizumab plus docetaxel in chemotherapy-naïve mcrpc
Published 1 year ago • 202 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
2:54
updated analysis of keynote-199: pembrolizumab for mcrpc previously treated with docetaxel
-
3:18
keynote-199: an update on pembrolizumab for mcrpc
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
0:37
antech's pet cancer speciality biopsy
-
2:28
new technology for prostate cancer detection and treatment
-
3:52
keynote 10: pembrolizumab vs docetaxel for nsclc
-
2:41
mri advances, office biopsies, and bladder cancer treatment and staging | backtable urology clips
-
1:57
keynote-010: pembrolizumab versus docetaxel in advanced pd-l1-positive nsclc
-
1:57
enzalutamide after docetaxel for mcrpc: evaluation by the italian named patient program
-
13:03
early tnbc - pembrolizumab chemotherapy: pathologic complete response in key subgroups
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
2:26
#esmo21 highlights on pembro chemo in 1st-line metastatic cervical cancer: the keynote-826 study
-
1:30
bmi and clinical outcomes in patients with metastatic castration-resistant prostate cancer
-
6:31
eau21 session “update on prostate cancer screening 2021”
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
8:45
keynote-590: pembrolizumab plus chemotherapy for advanced oesophageal cancer
-
2:09
dr. patel on early treatment with docetaxel for metastatic prostate cancer
-
2:17
advanced prostate cancer and patient-centric treatment
-
6:15
understanding your prostate cancer medical records | prostate cancer staging guide